Home    Back

Bortezomib/dexamethasone    (DrugBank: Bortezomib, Dexamethasone)

1 disease
IDDisease name (Link within this page)Number of trials
283Acquired pure red cell aplasia1

283. Acquired pure red cell aplasia    [ 17 clinical trials,   36 drugs,   (DrugBank: 19 drugs),   16 drug target genes,   91 drug target pathways]
Searched query = "Acquired pure red cell aplasia", "Pure red cell aplasia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 17 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04423367
(ClinicalTrials.gov)		September 13, 20205/6/2020Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line TreatmentSafety and Efficacy of Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment: A Prospective Phase II TrialAcquired Pure Red Cell AplasiaDrug: bortezomib/dexamethasoneInstitute of Hematology & Blood Diseases HospitalNULLRecruiting18 Years70 YearsAll17Phase 2China